| 摘要 |
<p>The invention relates to the use of the interferon alpha 5 in the treatment of viral hepatophaties. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the sub-type alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers and others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatophaties. The invention discloses in details such utilization in different forms and processes, including thoses which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.</p> |
